Epilepsy at Every Angle: A Systems Biology Approach to a Cure by Oprean, Amy
New Science
Volume 18 | Issue 1 Article 11
9-1-2010
Epilepsy at Every Angle: A Systems Biology
Approach to a Cure
Amy Oprean
Follow this and additional works at: http://digitalcommons.wayne.edu/newscience
This Article is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in New Science by an
authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Oprean, Amy (2010) "Epilepsy at Every Angle: A Systems Biology Approach to a Cure," New Science: Vol. 18: Iss. 1, Article 11.
Available at: http://digitalcommons.wayne.edu/newscience/vol18/iss1/11
P
A
G
E
 2
6
✼
Caused by birth trauma, malformation, stroke, brain tumor or head injury and affecting as 
much as 1 percent of the population, epilepsy is 
one of the least understood human disorders in the 
most complicated of organs – the brain. 
Groundbreaking work to unlock the disease’s 
cure is in motion in the lab of Jeffrey Loeb, M.D., 
Ph.D., associate professor of neurology, member of 
the WSU/DMC Comprehensive Epilepsy Program 
and associate director of the Center for Molecular 
Medicine and Genetics in the School of Medicine. 
By applying a systems biology approach to the 
study of human epileptic brain tissue, Loeb and 
his team are working to identify a “final common 
pathway” of genes consistently induced at human 
epileptic foci. Using this pathway as a drug target, 
Loeb and his team will work to develop drugs that 
successfully prevent epilepsy, first in rats, then  
in humans. 
This work is being performed with the Systems 
Biology of Epilepsy Project (SBEP), a multi-
disciplinary collaboration between Wayne State 
experts in areas ranging from neurosurgery to 
information technology. The project catalogs 
donated human epileptic brain tissues into an 
integrative, one-of-a-kind database, using the 
power of systems and computational biology 
to understand the disease through its electrical, 
anatomical and molecular features. Funded by 
WSU’s President’s Research Enhancement Program 
and the National Institutes of Health (NIH), 
the goals of the SBEP are to find biomarkers – 
substances or other characteristics that can be  
used for diagnosis – and drug targets for  
epilepsy therapeutics.  
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The project has several distinct advantages over 
other epilepsy research, one being the ability to 
study the disease in human brain tissue. “With 
many diseases, particularly those of the brain, 
researchers treat animals and then try to bring 
the treatment to patients, and that doesn’t always 
work,” Loeb said. “That’s why donated brain tissue 
is such an invaluable gift; it gives us the unique 
opportunity to start with the human disease and 
understand it at a level that we never could before.”
Another unique aspect of the project is its 
use of systems biology – the ability to obtain, 
integrate and analyze complex data from multiple 
experimental sources using interdisciplinary tools. 
“From the neurosurgeons performing brain-removal 
surgery to the IT experts that maintain our database, 
it’s the collaboration of first-rate researchers that 
makes this project work,” Loeb said. 
Donated from epilepsy patients who underwent 
brain surgery at Harper University Hospital and 
Children’s Hospital of Michigan, each epileptic 
tissue sample has a profile in the database that 
includes the patient’s clinical information, genes 
and proteins expressed and a 3-dimensional 
computer rendering of the tissue with a heat map 
of hot spots of electrical activity. The map identifies 
the location of seizures as well as interictal spikes 
– the minor, more frequent electrical discharges in 
the brain that occur between seizures.
The database can then process common 
characteristics and other relational information 
about the tissues. “We don’t look at one particular 
gene, pathway or protein, but at everything 
simultaneously and determine which variables are 
the most important to the diagnosis and treatment 
of epilepsy,” Loeb said.  “I am not aware of any 
other programs with a database that catalogs 
epileptic tissue so comprehensively.”
From animal model to  
human medicine
Loeb recently received NIH funding for a drug 
development facility and is partnering with drug 
companies to develop human drugs from his animal 
model. If successful, the human version of the drug 
will prevent human epilepsy in its early stages, 
before seizures ever occur. “I call it the epilepsy 
morning after pill,” Loeb said. “If you’re out riding 
a bike without a helmet and you fall and hit your 
head, taking this drug after the accident could 
prevent you from developing epilepsy.” 
Loeb will also investigate if the same drug can be 
used to cure epilepsy in patients months or years 
after a brain injury, when seizures begin.
Another major goal of the SBEP is improving 
diagnosis. Current noninvasive EEG techniques 
can only detect very large interictal spikes, with 
the more subtle electric activity requiring surgery 
in which the scalp is removed and electrodes are 
placed directly on the brain. Loeb is working  
to develop more powerful noninvasive  
screening methods. 
“By developing a method that gives us a higher 
resolution, we would dramatically improve our 
ability to treat epilepsy patients on a number of 
levels, from greater success in early diagnosis, to 
finding more biomarkers and developing better 
therapeutics,” Loeb said.  
Loeb will continue to build and maintain the 
database of epileptic tissue with the ultimate 
goals of developing diagnosis and disease-curing 
treatment for epilepsy at every stage by building 
and maintaining the project’s growing database of 
epileptic tissue. “We’re hoping to be successful on 
all fronts of disease diagnosis and prevention,” Loeb 
said. “This work would not be possible without the 
strong Wayne State expertise and the patients who 
allow us to study their brain tissue in hopes to put 
an end to this life-altering disease.”
To learn more, visit: http://www.sbep.wayne.edu/
joomla/index.php?option=com_frontpage&Itemid=1
and http://www.genetics.wayne.edu/jloeb
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About Dr. Jeffrey Loeb     
Dr. Loeb received his M.D. and Ph.D. in biochemistry 
and molecular biology, his S.M. in biochemistry and 
his A.B. in chemistry from the University of Chicago. 
Following  a neurology residency at Massachusetts 
General Hospital and postdoctoral work in the 
Department of Neurobiology at Harvard Medical 
School, he joined Wayne State University in 1998.
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